Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...

New research from the Exercise Medicine Research Institute at Edith Cowan University (ECU) has highlighted that children undergoing cancer treatment often lose skeletal muscle at a time when they ...

to develop a scoping review protocol that seeks to identify which procedures and for what purpose wearables available in the literature are being used on the masseter and temporal muscles. the ...

Basking in the glow of a collaboration involving Eli Lilly’s diabetes/weight loss blockbuster tirzepatide, BioAge Labs has completed an oversubscribed $170 million Series D financing, the proceeds of ...

Botox Halifax treatments have revolutionized the approach to facial rejuvenation, offering individuals a non-surgical solution for reducing wrinkles and fine lines. This innovative cosmetic procedure ...

SAN FRANCISCO -- Eating more protein may help offset some of the loss of lean mass during semaglutide (Ozempic, Wegovy) treatment, an observational prospective study suggested. After 3 months of ...

Non–muscle-invasive bladder cancer (NMIBC), seen in about 75% of newly diagnosed patients, is confined to the urothelial lining of the bladder and poses no immediate threat to life. However, almost 40 ...

CHICAGO — Combined use of semaglutide with an investigational monoclonal antibody called bimagrumab produced significant fat mass loss while preserving lean mass, results from the phase 2b BELIEVE ...

In summary, as the landscape of perioperative treatment paradigm continues to evolve, new trials exploring novel therapies and incorporating risk-adapted strategies are reshaping the management of ...

(RTTNews) - British drug major AstraZeneca Plc.'s (AZN, AZN.L) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...